

Why work with us?

- Pure-play viral vector CDMO, with purpose-built manufacturing facility
- Scale-up to clinical GMP production in less than 9 months
- Annex 1 compliant, with Swissmedic license for GMP manufacturing and testing
- From sequence to commercial vial under one roof with up to 1,000L GMP capacity
- 300+ batches produced, with 20+ sero- and pseudotypes
- World-class team from ~20 nations, headquartered in Zurich/ Switzerland
- Access to Siegfried's global network, including DP in Europe and U.S.



Find out more
about our gene therapy
success stories
dinamiqs.com

Get in touch with our experts!

info@dinamiqs.com



We transform genetic
medicine into success
stories


DINAMIQS provides a fully integrated, tailored manufacturing model offering its clients unmatched flexibility to advance their programs efficiently: from lead vector optimization via preclinical scale work, up to cGMP production in just 6-9 months.

Ensuring seamless continuity across the value chain, DINAMIQS accelerates timelines, reduces operational complexity, and safeguards product quality, allowing clients to move their programs from concept to commercialization with confidence.



Quality testing

- Ensure accuracy with advanced QC assays for AAV and LVV
- Shorten lead times with our in-house analytics and bioinformatics platform
- Identical analytical setup in R&D and GMP for seamless transition of methods



	DINAPEAK® AAV	DINAPEAK® LVV
Lead vector optimization	AI-enabled genome and capsid optimization to support performance, safety and manufacturability	Support for vector architecture and cassette optimization to balance efficacy, safety and manufacturability
Process development	DoE-driven upstream and downstream optimization, from small scale through 2 L process robustness studies	DoE-driven upstream and downstream optimization, from small scale through 2 L process robustness studies
Preclinical/ non-GMP manufacturing	Suspension-based, single-use manufacturing with GMP-compatible raw materials, from small scale to 50 L	Suspension-based, single-use manufacturing from small scale up to 50 L, including material for ex vivo and in vivo programs
cGMP manufacturing	20 L-1,000 L manufacturing using fully closed, single-use suspension processes	20 L-1,000 L manufacturing using fully closed, single-use suspension processes
Advanced purification	Chromatography and ultracentrifugation-based approaches, including optimization for full/ empty capsid separation delivering up to ~90% full ratios with intensified purification	Integrated clarification, TFF and chromatography for purification, concentration and formulation
Integrated fill-finish	In-house aseptic vial filling with an isolator technology	In-house aseptic vial filling with an isolator technology